Applications of N-[(S)-1-Carbethoxy-1-Butyl]-(S)-Alanine in Industrial Manufacturing

As an experienced manufacturer specializing in advanced chiral building blocks, we supply N-[(S)-1-Carbethoxy-1-Butyl]-(S)-Alanine to downstream industries with validated high-purity material for use in sophisticated synthesis environments. The following application scenarios highlight real-world industrial settings where this compound delivers tangible value through consistent product quality and reliable process integration.

1. Peptide and API Intermediate Synthesis

Pharmaceutical manufacturers use this chiral amino acid derivative as a key intermediate in the stepwise synthesis of peptides and small-molecule active pharmaceutical ingredient (API) programs requiring defined stereochemistry. Its structure provides essential chirality transfer in protected peptide chain assembly and in the preparation of α-amino acid-based pharmaceuticals by solution-phase or solid-phase peptide synthesis (SPPS). Stringent purity selection is necessary to meet regulatory requirements, and production batches must demonstrate traceable incoming inspection records to support GMP and DMF submissions.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.) applicable monographs for intermediates
• US FDA 21 CFR Part 211 for finished pharmaceuticals (as relevant for intermediates)
• ISO 9001:2015 certified quality systems

Typical usage ratio

• Usually 0.8–1.2 mol equivalents relative to coupling partner, adjusted based on desired peptide sequence and excess considerations to minimize racemization.

Downstream process integration

• Material is charged at the peptide bond-forming stage, after pre-activation with coupling agents, following Fmoc/t-Boc protection protocols for solution or solid phase synthesis.

Final product types

• Peptide APIs (therapeutic oligopeptides)
• Chiral pharmaceutical intermediates
• Final step protected/unprotected amino acids for research and clinical use
• Building blocks for anticancer/antiviral drug candidates

2. Enzyme Substrate Preparation for Biocatalysis Screening

Biotech and specialty enzyme manufacturers rely on this chiral amino acid derivative as a reference substrate for enzyme selectivity and activity evaluation, particularly in the development of lipases, proteases, and esterases supporting enantioselective transformations. Its enantiopure configuration helps validate enzyme performance in high-throughput screening and kinetic resolution studies, supporting data for technical dossiers and regulatory submissions for process enzymes.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP)
• ISO/IEC 17025 laboratory accreditation for test methods
• REACH registration for research use in Europe
• Enzyme producer SOPs for analytical control and traceability

Typical usage ratio

• Typically 0.1–3 mmol per assay setup, optimized according to substrate turnover rate and enzyme loading in miniaturized screening formats.

Downstream process integration

• Direct use as input material in substrate-specific enzyme assays, typically dissolved or suspended in assay buffer, prior to introduction of the catalyst preparation.

Final product types

• Validated enzyme formulations for chiral chemical manufacturing
• Enzyme activity test kits for industrial and academic laboratories
• Technical dossiers for regulatory submissions
• Reference standards used in process development

3. Specialty Amino Acid Derivatives for Custom Polymer Synthesis

Producers of functional polymers and advanced materials use chiral amino acid derivatives to create specialty resins, coatings, and biodegradable materials for electronics and medical applications. Incorporating this intermediate into polymer backbones enables control over monomer chirality, which impacts final polymer properties such as bioresorption rate, optical activity, or material strength in application-specific engineered products.

Industry compliance standards

• ISO 13485:2016 for medical-grade materials
• USP Class VI plastics certification for biomedical polymers
• RoHS Directive for electronics components
• ISO 14001 for environmental management in production

Typical usage ratio

• Monomer feed fraction 1–15% depending on target polymer architecture and required degree of chirality-induced functionalization.

Downstream process integration

• Added during the initial polymerization or co-polymerization step, either as-is or after activation, to deliver chiral functionality within the forming polymer matrix.

Final product types

• Bioresorbable medical scaffolds
• Chiral stationary phases for chromatography
• Optically active resins for electronics encapsulation
• Functionalized coatings with specific enantioselective properties

4. Chiral Auxiliary Sourcing for Asymmetric Synthesis

Fine chemical manufacturers and research organizations deploy this amino acid derivative as a chiral auxiliary or ligand precursor in asymmetric catalytic transformations. It enables high stereoselectivity when synthesizing enantioenriched products at gram-to-kilogram scale, serving as a critical component in steps like enantioselective alkylation, Michael addition, or aldol reaction systems. Analytical batch release and full traceability are critical for downstream process validation.

Industry compliance standards

• ISO 9001:2015 process validation documentation
• GMP for starting materials as specified in ICH Q11 (when used for pharmaceutical production)
• REACH and TSCA compliance for industrial scale-up
• Company-specific supplier audit requirements

Typical usage ratio

• 0.9–1.5 molar equivalents relative to the target prochiral substrate, adjusted to reaction kinetics and product recovery optimization.

Downstream process integration

• Introduced at the chiral induction step, often after pre-complexation or activation, prior to the main asymmetric transformation in batch or flow reactors.

Final product types

• Enantioenriched specialty fine chemicals
• Advanced pharmaceutical intermediates
• Asymmetric reduction or alkylation products
• Evaluation batches for new catalyst systems